



Building *The* Retina Company

Trading Update and Daytona Unveiling

Roy Davis, CEO

Christine Soden, CFO

David Iannetta, Director Strategic Marketing

Dr David Nelson, Chairman Optos Optometry Advisory Council

13th October 2011



Forward-Looking Statements



Certain statements made in this presentation are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates and projections about its industry, its beliefs and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this presentation. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Trading Update

Strong Full Year Performance



Strong Q4 performance with annual revenues ahead of consensus and underlying* full year revenue growth in excess of 25%

- Revenues ahead of analysts consensus
- Absolute growth over prior year in excess of 30%
- Underlying* growth of over 25%
- Installed base increased 8% to 4,240 devices globally
- Daytona device unveiled as planned at the American Academy of Optometry in Boston – commercial shipments planned for Q1 2012

** Note – Underlying is calculated by treating all payments from rental contracts as operating leases and including revenues from outright device sales but excluding revenues from Opto Global and Accutome products.*

Unveiling *Daytona*

Our Current Ultra-Widefield Products



P200



Core Optometry
Market
Retail / Wellness

200Dx™



Clinical Optometry
Wellness / Some
Referral
+Image Quality

P200C



Clinical Optometry
(US)
General
Ophthalmology
Globally
++Image Quality

200Tx™



General Ophthalmology
/ Vit Ret
Disease Management
and Treatment
++Image Quality
AutoFluorescence
Fluorescein
Angiography

Increased functionality

Daytona is designed to enable Optos to ‘globalise’ our core widefield retinal imaging technology

- 200 degree widefield retinal fundus imaging – Colour and AutoFluorescence (AF) modalities
- Aimed at Optometrists in North America and both Optometrists and General Ophthalmologists elsewhere
- Small footprint, desktop, easy to ship
- Improved image quality – equivalent to P200C product or better
- Improved user and patient interaction – improved ease of use
- ‘Plug ‘n’ play’ – no complex installation, minimal user training (<1hr)
- Designed for high volume manufacturing and to be serviceable in the field
- Designed for the global market (addresses dust management in certain environments)
- Suitable for both capital sale or Pay Per Patient rental business models

The Result – A ‘Game Changer’

The Product will be marketed as *Daytona*



Daytona - Revolutionising Eyecare Globally



Daytona – A ‘Game Changer’

What Colour Will You Choose?




Image Performance

Clinically Superior Capabilities



Daytona Image Quality Compared to 200Dx



- Brighter in Periphery
- Better Detail in Central Pole
- Addition of AutoFluorescence (AF) capability

Positive market feedback

“The Daytona device really has the potential to be a game-changing technology for Optos in the market.”

Dr David Nelson, OD, Past President of The American Optometric Association

“Optos’ s ultra-wide angle imaging when combined with traditional techniques, offers practitioners an opportunity to clinically improve their disease detection, which provides better care for patients, and is what we all strive for.”

Dr Kristen Brown, OD, FAAO, New England College of Optometry

“Ultra-widfield AF gives doctors the ability to see the lipofuscin buildup. To see the cellular activity. To see what they can’ t see with traditional tools.”

Dr Jerry Sherman, OD, FAAO, SUNY School of Optometry


Product Positioning & Pricing

Daytona - Filling The Gap



Optometry Market

Ophthalmology Market



Our Current Ultra-Widefield Products



P200



Core Optometry
Market
Retail / Wellness

200Dx™



Clinical Optometry
Wellness / Some
Referral
+Image Quality

P200C



Clinical Optometry
(US)
General
Ophthalmology
Globally
++Image Quality

Daytona



Launch 2012
Clinical Optometry
(US)
General
Ophthalmology
Globally
++Image Quality
AutoFluorescence

200Tx™



General
Ophthalmology /
Vit Ret
Disease
Management and
Treatment
++Image Quality
AutoFluorescence
Fluorescein
Angiography

Increased functionality

Unveiling Daytona

American Academy of Optometry in Boston



- New innovative show booth
- Designed for impact
- Clinical lectures supporting product launch

- Supported by trade advertising campaign




Unveiling Daytona

Supported By A Special Daytona Microsite



For More Information regarding Daytona specifics, please visit:

➤ www.optosnextgen.com



Summary

Daytona – The Next Generation Optos Product



- Daytona – an improved ultra widefield product offering
 - Improved product performance – colour and af imaging modalities
 - Smaller
 - Improved ease of use
 - Cheaper to install and maintain; manufacturing cost target achievable
 - Leading edge design
 - Colour customisable
- Positive initial clinician reaction – clinical trials planned
- Priced to protect core markets and generate incremental growth
- Extensive marketing programme to support planned launch
- On track for planned Q1 calendar 2012 launch
- Phased roll out plan driven by regulatory timing
- Further details to be discussed at 2nd November event



Daytona – globalising ultra-widefield imaging